Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Phase 3 Study of Acupression's Bracelets in Nausea and Vomiting Induced by FEC100 Chemotherapy's Sort.

This study has been completed.
Information provided by:
Institut Claudius Regaud Identifier:
First received: December 21, 2005
Last updated: March 17, 2009
Last verified: March 2009
The purpose of this study is to demonstrate a betterment of the digestive symptomatology by the anti-emetic acupression's bracelets's use associated with hygiene and dietetic advices.

Condition Intervention Phase
Breast Neoplasms
Device: Acupression's bracelet
Behavioral: Hygiene and dietetic advices
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Prevention
Official Title: Evaluation of Acupression's Bracelets Associated to an Educational Step Versus Education Only in Nausea and Vomiting's Mastering Induced by FEC100 Chemotherapy's Sort.

Resource links provided by NLM:

Further study details as provided by Institut Claudius Regaud:

Primary Outcome Measures:
  • Reduction of 15% of stage III/IV nausea and vomiting's incidence.

Estimated Enrollment: 347
Study Start Date: February 2006
Study Completion Date: December 2007
Primary Completion Date: December 2007 (Final data collection date for primary outcome measure)

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Woman
  • Age > 18 years
  • Well-informed written consent, signed by the patient before the beginning of the study
  • Breast cancer's diagnosis (operated or not)
  • Forecast of a treatment by FEC100 chemotherapy's sort (D1=D21) during at least 3 cycles.
  • Patient affiliated at a welfare or beneficiary from it
  • Investigator estimates that the patient is able to conform with protocol's conditions and to respect them

Exclusion Criteria:

  • Operated arm's lymphedema
  • Wrist's morphology which cannot permit the bracelet's wearing (20 cm)
  • D1=D15 FEC100's treatment
  • Psychic incapability to sign a well-informed consent
  • Refusal to give a written consent
  • Patient under tutelage or guardianship
  • Pregnant or breast-feeding woman
  • Any clinical trial's participation which would impose nausea and vomiting's treatment modalities
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00268125

Centre Oscar Lambret
Lille, France
Centre Paul STRAUSS
Strasbourg, France
Institut Claudius Regaud
Toulouse, France
Sponsors and Collaborators
Institut Claudius Regaud
Principal Investigator: Jean-Pierre DELORD, Dr Institut Claudius Regaud
  More Information

Responsible Party: Dr Jean-Pierre DELORD, Institut Claudius Regaud Identifier: NCT00268125     History of Changes
Other Study ID Numbers: 05 DIVE 05
Study First Received: December 21, 2005
Last Updated: March 17, 2009

Keywords provided by Institut Claudius Regaud:
Breast Neoplasm

Additional relevant MeSH terms:
Breast Neoplasms
Signs and Symptoms, Digestive
Signs and Symptoms
Neoplasms by Site
Breast Diseases
Skin Diseases processed this record on April 26, 2017